Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-07-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
第四届董事会第三十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 33rd meeting of the 4th Board of Directors of Lingkang Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, and voting results on specific proposals, including the downward adjustment of convertible bond conversion price and the convening of an extraordinary general meeting. The document is a board meeting resolution announcement, not a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a shareholder voting result announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board decisions, consistent with MANG filings.
2025-07-14 Chinese
关于董事会提议向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of Lingkang Pharmaceutical Group Co., Ltd. regarding a proposal to downward adjust the conversion price of its convertible bonds (referred to as 'Lingkang Convertible Bonds'). It details the background, regulatory approvals, bond issuance, previous adjustments, the triggering event for the price adjustment, and the board's proposal to submit this adjustment to the shareholders' meeting for approval. The document is a formal announcement of a corporate action related to capital structure (adjustment of convertible bond conversion price) and the upcoming shareholder vote on this matter. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is a capital/financing update about convertible bond terms and related corporate governance steps. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 2442 characters, which is consistent with an announcement rather than a full report.
2025-07-14 Chinese
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of the convertible bond's conversion price adjustment conditions. It details the bond's basic information, the adjustment clauses, the possible triggering situation, and the company's obligations to disclose further information. The document is regulatory in nature, providing a compliance update about convertible bond price adjustments under Shanghai Stock Exchange rules. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report but a regulatory announcement about a potential price adjustment event. Therefore, it fits best under Regulatory Filings (RNS). The document length is 2738 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-07-07 Chinese
可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related changes in share capital for Lingkang Pharmaceutical Group Co., Ltd. It details the amount of convertible bonds converted into shares, the remaining unconverted bonds, and the changes in share capital as of specific dates. The document includes regulatory approval references and specific bond codes but does not contain comprehensive financial statements or detailed financial performance data. It is a formal disclosure of bond conversion results and share capital changes, fitting the category of Share Issue/Capital Change announcements rather than a full financial report or other types of filings.
2025-07-02 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, previous adjustments to the conversion price, the triggering conditions for a downward adjustment, and the board's resolution not to exercise the right to adjust the conversion price downward at this time. The document is a formal disclosure about a capital/financing matter related to convertible bonds and their conversion price adjustments. It is not a full financial report, earnings release, or management discussion, but rather a specific update on financing terms and board decisions related to capital instruments. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and contains substantive content about financing terms, not just a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2025-06-23 Chinese
关于召开2024年度暨2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a performance explanation meeting (业绩说明会) for the 2024 annual and 2025 first quarter results. It provides the meeting time, location, participation method, and contact information. It explicitly states that the company has already disclosed the 2024 annual report and 2025 first quarter report on the stock exchange website. The document does not contain actual financial data or detailed financial analysis but serves as a notice for an upcoming investor presentation event where these results will be discussed. Therefore, it is not the report itself (like 10-K or IR) but an announcement of a meeting to explain the results, fitting the category of Investor Presentation (IP). The document length is short (1364 characters), but it is not merely a report publication announcement since it details the meeting logistics and participation instructions, which aligns with an Investor Presentation announcement.
2025-06-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.